RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2―Negative Metastatic Breast CancerBRUFSKY, Adam M; HURVITZ, Sara; PEREZ, Edith et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4286-4293, issn 0732-183X, 8 p.Article

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung CancerHIRSCH, Fred R; VARELLA-GARCIA, Marileila; DZIADZIUSZKO, Rafal et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 6317-6323, issn 1078-0432, 7 p.Article

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. CommentaryYAUCH, Robert L; JANUARIO, Thomas; MODRUSAN, Zora et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8534-8537, issn 1078-0432, 17 p., 1Article

Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung CancerSPIGEL, David R; MING LIN; O'NEILL, Vincent et al.Cancer. 2008, Vol 112, Num 12, pp 2749-2755, issn 0008-543X, 7 p.Article

Improving the effectiveness of continuous closed chest compressions: an exploratory studyHUSEYIN, Turan S; MATTHEWS, Amanda J; WILLS, Paul et al.Resuscitation. 2002, Vol 54, Num 1, pp 57-62, issn 0300-9572Article

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancerHERBST, Roy S; O'NEILL, Vincent J; FEHRENBACHER, Louis et al.Journal of clinical oncology. 2007, Vol 25, Num 30, pp 4743-4750, issn 0732-183X, 8 p.Article